COMMUNIQUÉS West-GlobeNewswire
-
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
15/09/2024 - 14:45 -
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
15/09/2024 - 14:45 -
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
15/09/2024 - 15:45 -
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
14/09/2024 - 01:38 -
Company Statement on FDA Advisory Committee Meeting
14/09/2024 - 01:40 -
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
14/09/2024 - 08:30 -
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
14/09/2024 - 08:30 -
Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors
14/09/2024 - 09:00 -
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
14/09/2024 - 09:00 -
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
14/09/2024 - 09:00 -
RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
14/09/2024 - 09:15 -
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
14/09/2024 - 09:30 -
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
14/09/2024 - 10:15 -
KFSHRC Revolutionizes Patient Care with Pioneering Experience Ambassadors Program
14/09/2024 - 13:11 -
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
14/09/2024 - 13:30 -
RYBREVANT®▼ (amivantamab) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
14/09/2024 - 16:00 -
Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19
13/09/2024 - 13:00 -
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
13/09/2024 - 13:00 -
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
13/09/2024 - 13:00
Pages